Dosing Begins in Phase 2 Trial of Mezagitamab, Antibody to Treat MG
A first person has been dosed in a Phase 2 trial evaluating mezagitamab (TAK-079), Takeda Pharmaceutical’s investigational antibody, as a therapy for generalized myasthenia gravis (MG), according to a press release. The trial (NCT04159805), beginning to enroll at select sites across the U.S., Canada, Italy, Poland,…